Management of castration-resistant prostate cancer: bisphosphonates and emerging therapies.
Approximately 70% of patients with prostate cancer will develop bone metastases that often lead to bone pain and skeletal-related events. Several bisphosphonates have shown promising activity for palliating pain. Only zoledronic acid has significantly delayed the onset and reduced the incidence of skeletal-related events in men with castration-resistant prostate cancer. In addition, studies suggest that bisphosphonates have anticancer activity that may prevent disease progression and improve survival. Clodronate was shown to improve survival in a study of men with metastatic androgen-sensitive prostate cancer. Emerging therapies are being investigated for their ability to maintain bone health. The findings presented herein highlight the importance of bone-targeted therapies for patients with bone metastases from prostate cancer.
Centre Hospitalier de l'Université de Montréal, Hôpital Notre-Dame, Canada. fred.saad@umontreal.ca
Fred
F
Saad
Marc
M
Colombel
D000970:Antineoplastic Agents / Q000494:pharmacology / Q000627:therapeutic use; D050071:Bone Density Conservation Agents / Q000494:pharmacology / Q000627:therapeutic use*; D001859:Bone Neoplasms / Q000188:drug therapy* / Q000556:secondary; D004164:Diphosphonates / Q000494:pharmacology / Q000627:therapeutic use; D006801:Humans; D008297:Male; D009919:Orchiectomy / Q000379:methods; D010146:Pain / Q000188:drug therapy / Q000209:etiology; D010166:Palliative Care / Q000379:methods; D011471:Prostatic Neoplasms / Q000473:pathology* / Q000601:surgery; D013534:Survival
D000970:Antineoplastic Agents; D050071:Bone Density Conservation Agents; D004164:Diphosphonates